EUROIMMUN
→
PerkinElmer (Revvity)
Acquisition · Cash · announced Jun 16, 2017
Announced
Jun 16, 2017
Closed
Dec 19, 2017
Economics
Cash()
Pre-deal · pre-deal mark: 2017, year precision · rounding grid ±$100M · PerkinElmer 8-K filing, SEC EDGAR — EUROIMMUN acquisition
~$1.3B cash
Target
EUROIMMUN
Diagnostics · Diagnostic / genomic
HQ Lübeck, Germany · Founded 1987
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
Acquirer
PerkinElmer (Revvity)
Healthcare
HQ Waltham, MA
Life sciences and diagnostics company — reproductive health, newborn screening, autoimmune diagnostics; rebranded diagnostics business as Revvity (2023)
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Global autoimmune diagnostics leader — drives EUROIMMUN's capabilities into PerkinElmer's US reproductive health channel; 19% revenue CAGR; operations in 130+ countries with 45% revenue from China
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
Tertiary (trade / analyst)
Revvity investor relations — completion (Dec 19, 2017)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/31791/000119312517206411/d410886d8k.htm
Open source
Limitations
- ~$1.3B cash
- Pre-deal valuation sourced from: PerkinElmer 8-K filing, SEC EDGAR — EUROIMMUN acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| Counsyl | Myriad Genetics | May 28, 2018 | same evidence class | |
| Sequenom | LabCorp | Jul 27, 2016 | same evidence class | |
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 | ||
| nVision Medical | Boston Scientific | Apr 16, 2018 |
Other verified deals by PerkinElmer (Revvity)
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by PerkinElmer (Revvity) are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — EUROIMMUN (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.